Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Mylan"

27 News Found

Private equity firm Carlyle partners with Viyash Life Sciences for pharma platform
News | November 17, 2021

Private equity firm Carlyle partners with Viyash Life Sciences for pharma platform

Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players


Glenmark receives ANDA approval for treatment of acne
Drug Approval | September 21, 2021

Glenmark receives ANDA approval for treatment of acne

Clindamycin Phosphate Foam, 1% is the generic version of Evoclin Foam, 1%


Semglee approval to provide huge opportunities in the US insulin biosimilar market
Biotech | August 19, 2021

Semglee approval to provide huge opportunities in the US insulin biosimilar market

FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.


Five manufacturers get license to produce Black Fungus drug
News | May 23, 2021

Five manufacturers get license to produce Black Fungus drug

NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers


Remdesivir production increased to 119 lakh vials per month
News | May 18, 2021

Remdesivir production increased to 119 lakh vials per month

Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60


Biosimilars performance below expectations for Biocon : ICICI Direct
Biotech | May 03, 2021

Biosimilars performance below expectations for Biocon : ICICI Direct

The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.


Lupin launches penicillamine tablets USP
News | March 04, 2021

Lupin launches penicillamine tablets USP

Penicillamine Tablets USP, 250 mg (RLD: Depen) had estimated annual sales of USD 5 million in the U.S. (IQVIA MAT December 2020).